C. Laforce

发表

Efficacy and tolerability of once-daily budesonide/formoterol pressurized metered-dose inhaler in adults and adolescents with asthma previously stable with twice-daily budesonide/ formoterol dosing.

E. Kerwin, B. Parasuraman, Christopher J. Miller, 2009, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patients.

F. Martinez, C. Crim, M. Dransfield, 2014, Respiratory medicine.

Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial.

M. Kavuru, C. Laforce, B. Prillaman, 2000, The Journal of allergy and clinical immunology.

Fluticasone propionate aerosol for the treatment of adults with mild to moderate asthma. The Fluticasone Propionate Asthma Study Group.

R. Dockhorn, A. van As, E. Bronsky, 1994, The Journal of allergy and clinical immunology.

Fluticasone propionate aerosol: efficacy in patients with mild to moderate asthma. Fluticasone Propionate Asthma Study Group.

A. Sheffer, C. Laforce, D. Pearlman, 1996, The Journal of family practice.

Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 study

G. Feldman, F. Patalano, P. D’Andrea, 2016, International journal of chronic obstructive pulmonary disease.

Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 study

G. Feldman, F. Patalano, P. D’Andrea, 2016, International journal of chronic obstructive pulmonary disease.

Profiling the bronchodilator effects of the novel ultra-long-acting β2-agonist indacaterol against established treatments in chronic obstructive pulmonary disease

H. Magnussen, C. Vogelmeier, B. Kramer, 2011, Therapeutic advances in respiratory disease.

Influence of C-159T SNP of the CD14 gene promoter on lung function in smokers.

Haibo Zhou, N. Alexis, D. Peden, 2009, Respiratory medicine.

Efficacy and Safety of Formoterol Delivered Via a New Multidose Dry Powder Inhaler (Certihaler™) in Adolescents and Adults with Persistent Asthma

B. Prenner, C. Laforce, Ü. Yegen, 2004, The Journal of asthma : official journal of the Association for the Care of Asthma.

Randomized controlled trial evaluating the clinical benefit of montelukast for treating spring seasonal allergic rhinitis.

M. Malice, T. Reiss, J. Menten, 2003, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Montelukast for treating seasonal allergic rhinitis: a randomized, double‐blind, placebo‐controlled trial performed in the spring

M. Malice, T. Reiss, F. Hampel, 2002, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) in the treatment of seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial of efficacy and safety.

E. Meltzer, D. Price, P. Ratner, 2012, Allergy and asthma proceedings.

Comparison of olopatadine 0.6% nasal spray versus fluticasone propionate 50 microg in the treatment of seasonal allergic rhinitis.

S. Spector, M. Kaliner, B. Chipps, 2009, Allergy and asthma proceedings.

Sustained 24-hour efficacy of once daily indacaterol (300 μg) in patients with chronic obstructive pulmonary disease: a randomized, crossover study.

A. Iqbal, B. Kramer, M. Higgins, 2011, Pulmonary pharmacology & therapeutics.

Efficacy and safety of dry powder fluticasone propionate in children with persistent asthma.

W. Silvers, S. Duke, C. Laforce, 2000, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

The safety of twice-daily treatment with fluticasone propionate and salmeterol in pediatric patients with persistent asthma.

P. Dorinsky, S. Nimmagadda, C. Laforce, 2005, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

S. Szefler, R. Schwartz, E. Bronsky, 1998, The Journal of pediatrics.

The 24-Hour FEV1 Time Profile of Olodaterol Once Daily (QD) via Respimat® and Formoterol Twice Daily (BID) via Aerolizer® in Patients With COPD: Results From Two 6-Week Studies

J. Bernstein, G. Feldman, C. Laforce, 2013 .

Safety of formoterol in patients with asthma: combined analysis of data from double-blind, randomized controlled trials.

F. Radner, C. Bonuccelli, H. Nelson, 2010, The Journal of allergy and clinical immunology.

Bronchodilator efficacy of indacaterol, a novel once-daily beta2-agonist, in patients with persistent asthma.

M. Higgins, R. Owen, C. Laforce, 2008, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Formoterol, 24 microg bid, and serious asthma exacerbations: similar rates compared with formoterol, 12 microg bid, with and without extra doses taken on demand, and placebo.

A. van As, W. Sokol, G. Della Cioppa, 2006, Chest.

Growth in asthmatic children treated with fluticasone propionate. Fluticasone Propionate Asthma Study Group.

R. Nathan, P. Konig, D. Tinkelman, 1998, The Journal of pediatrics.

Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis.

R. Dockhorn, W. Busse, T. Casale, 1997, The Journal of allergy and clinical immunology.

Randomized, double-blind, placebo-controlled study of montelukast for treating perennial allergic rhinitis.

William H. Yang, T. Reiss, F. Horak, 2005, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Effect of Vitamin D3 on Asthma Treatment Failures in Adults With Symptomatic Asthma and Lower Vitamin D Levels:

Lisa, Tonya S. King, E. R. Sutherland, 2014 .

A dose-ranging study of fluticasone propionate aqueous nasal spray for seasonal allergic rhinitis assessed by symptoms, rhinomanometry, and nasal cytology.

E. Meltzer, R. Lemanske, E. Bronsky, 1990, The Journal of allergy and clinical immunology.

Once-daily ciclesonide improves lung function and is well tolerated by patients with mild-to-moderate persistent asthma.

E. Kerwin, C. Laforce, W. Berger, 2005, The Journal of allergy and clinical immunology.

Efficacy of azelastine nasal spray in seasonal allergic rhinitis patients who remain symptomatic after treatment with fexofenadine.

J. Corren, C. Laforce, W. Berger, 2004, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Onset of action of mometasone furoate nasal spray (NASONEX®) in seasonal allergic rhinitis

C. Laforce, D. Bernstein, A. Rooklin, 1999, Allergy.

Safety and efficacy of azelastine nasal spray (Astelin NS) for seasonal allergic rhinitis: a 4-week comparative multicenter trial.

R. Dockhorn, B. Prenner, C. Laforce, 1996, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Once daily intranasal fluticasone propionate is effective for perennial allergic rhinitis.

M. Blumenthal, C. Laforce, D. Pearlman, 1994, Annals of allergy.

Fluticasone propionate aqueous nasal spray compared with terfenadine tablets in the treatment of seasonal allergic rhinitis.

J. Weiler, R. Dockhorn, E. Meltzer, 1996, The Journal of allergy and clinical immunology.

Use of nasal steroids in managing allergic rhinitis.

C. Laforce, Craig LaForce, 1999, The Journal of allergy and clinical immunology.

Effects of the inhaled corticosteroids fluticasone propionate, triamcinolone acetonide, and flunisolide and oral prednisone on the hypothalamic-pituitary-adrenal axis in adult patients with asthma.

L. Edwards, W. Lincourt, C. Sorkness, 1999, Clinical therapeutics.

Once-daily indacaterol 75 μg in moderate- to-severe COPD: results of a Phase IV study assessing time until patients’ perceived onset of effect

F. Kianifard, T. Siler, C. Laforce, 2014, International journal of chronic obstructive pulmonary disease.

Effect of cetirizine on symptom severity and quality of life in perennial allergic rhinitis.

R. Nathan, David Skoner, C. Laforce, 2014, Allergy and asthma proceedings.

Dose-ranging study of a new steroid for asthma: mometasone furoate dry powder inhaler.

G. Settipane, J. Kemp, D. Bernstein, 1999, Respiratory medicine.

Formoterol Delivered via the Dry Powder Aerolizer® Inhaler Versus Albuterol MDI and Placebo in Mild-to-Moderate Asthma: A Randomized, Double-Blind, Double-Dummy Trial

G. Della Cioppa, C. Laforce, W. Pleskow, 2003, The Journal of asthma : official journal of the Association for the Care of Asthma.

QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease

J. V. van Noord, R. Buhl, C. Laforce, 2010, Thorax.

Effects on Pulmonary Function of Once-Daily (qd) Budesonide and Formoterol Administered via One Pressurized Metered-Dose Inhaler (pMDI) in Adults and Adolescents With Asthma Previously Stable With Twice-Daily (bid) Budesonide/Formoterol pMDI

E. Kerwin, Christopher J. Miller, J. Oppenheimer, 2008 .

Asthma Control with Once-Daily (qd) Budesonide/Formoterol Pressurized Metered-Dose Inhaler (pMDI) in Adults and Adolescents with Asthma Previously Stable with Twice-Daily (bid) Budesonide/Formoterol pMDI

E. Kerwin, Christopher J. Miller, J. Oppenheimer, 2008 .

Safety of Once-Daily (qd) Budesonide and Formoterol Administered via One Pressurized Metered-Dose Inhaler (pMDI) in Adults and Adolescents With Asthma Previously Stable With Twice-Daily (bid) Budesonide/Formoterol pMDI

E. Kerwin, Christopher J. Miller, J. Oppenheimer, 2008 .

Once daily fluticasone propionate aqueous nasal spray is an effective treatment for seasonal allergic rhinitis.

R. Nathan, R. Lemanske, E. Bronsky, 1991, Annals of allergy.

Albuterol multidose dry powder inhaler efficacy and safety versus placebo in children with asthma.

H. Taveras, H. Iverson, Paul M. Shore, 2017, Allergy and asthma proceedings.

A 26-week Tolerability Study of Ciclesonide Nasal Aerosol in Patients with Perennial Allergic Rhinitis

C. Laforce, W. Berger, G. Raphael, 2012, American journal of rhinology & allergy.

Efficacy and safety of ciclesonide, 200 μg once daily, for the treatment of perennial allergic rhinitis

E. Meltzer, S. Kunjibettu, C. Laforce, 2007 .

Montelukast Effectively Treats the Nighttime Impact of Seasonal Allergic Rhinitis

N. Santanello, E. Meltzer, M. Malice, 2005, American journal of rhinology.

Salmeterol powder compared with albuterol aerosol as maintenance therapy for asthma in adolescent and adult patients.

J. Kemp, E. Ståhl, C. Laforce, 1998, Clinical therapeutics.

Long-term, double-blind comparison of controlled-release albuterol versus sustained-release theophylline in adolescents and adults with asthma.

W. Pierson, D. Tinkelman, C. Laforce, 1990, The Journal of allergy and clinical immunology.

A randomized study of BI 671800, a CRTH2 antagonist, as add-on therapy in poorly controlled asthma.

E. Bateman, C. Wood, Abhya Gupta, 2017, Allergy and asthma proceedings.

Fluticasone propionate hydrofluoroalkane inhalation aerosol in patients receiving inhaled corticosteroids.

C. Crim, W. Lumry, M. M. Conway, 2006, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Effect of vitamin D3 on asthma treatment failures in adults with symptomatic asthma and lower vitamin D levels: the VIDA randomized clinical trial.

Tonya S. King, E. R. Sutherland, M. Cabana, 2014, JAMA.

464 Fluticasone propionate (FP) aerosol in asthma

R. Dockhorn, E. Bronsky, J. Seltzer, 1991 .

Ciclesonide, a novel inhaled steroid, has no effect on hypothalamic-pituitary-adrenal (HPA)-axis function in mild-to-moderate asthmatics*

S. Rohatagi, C. Laforce, D. Banerji, 2003 .

Randomized, placebo-controlled study of cetirizine and loratadine in children with seasonal allergic rhinitis.

Mitesh K. Patel, C. Laforce, W. Berger, 2017, Allergy and asthma proceedings.

A Randomized, Double-Blind, Parallel-Group, Multicenter, Placebo-Controlled Study of the Safety and Efficacy of Extended-Release Guaifenesin/Pseudoephedrine Hydrochloride for Symptom Relief as an Adjunctive Therapy to Antibiotic Treatment of Acute Respiratory Infections

D. Gentile, David Skoner, C. Laforce, 2008, Postgraduate medicine.

Effect of erythromycin on theophylline clearance in asthmatic children.

M. Miller, C. Laforce, H. Chai, 1981, The Journal of pediatrics.

A comparison of once-daily triamcinolone acetonide aqueous and twice-daily beclomethasone dipropionate aqueous nasal sprays in the treatment of seasonal allergic rhinitis.

J. Murray, W. Lumry, F. Hampel, 2003, Allergy and asthma proceedings.

Efficacy and safety of ciclesonide hydrofluoroalkane nasal aerosol once daily for the treatment of seasonal allergic rhinitis.

E. Meltzer, C. Laforce, M. Wingertzahn, 2009, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma.

J. Kemp, R. Dockhorn, A. van As, 1992, The New England journal of medicine.

Efficacy and Safety of Once-Daily Ciclesonide Nasal Spray in Children With Allergic Rhinitis

H. Kaiser, B. Lanier, C. Laforce, 2008 .

Fluticasone propionate: an effective alternative treatment for seasonal allergic rhinitis in adults and adolescents.

R. Dockhorn, E. Meltzer, R. Nathan, 1994, The Journal of family practice.

Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma

W. White, S. Miller, G. Robbie, 2011, BMC pulmonary medicine.

Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial.

T. Casale, A. Racine, J. Condemi, 2001, JAMA.

Efficacy and safety of inhaled zanamivir in the prevention of influenza in community-dwelling, high-risk adult and adolescent subjects: a 28-day, multicenter, randomized, double-blind, placebo-controlled trial.

F. Henderson, Julia H N Harris, F. Hampel, 2007, Clinical therapeutics.

Randomized, double-blind, placebo-controlled, safety and immunogenicity study of 4 formulations of Anthrax Vaccine Adsorbed plus CPG 7909 (AV7909) in healthy adult volunteers.

T. Rudge, E. Bernton, R. Hopkins, 2013, Vaccine.

Two-week comparison study of olopatadine hydrochloride nasal spray 0.6% versus azelastine hydrochloride nasal spray 0.1% in patients with vasomotor rhinitis.

E. Meltzer, P. Lieberman, C. Laforce, 2011, Allergy and asthma proceedings.

Kimura's disease: report of a pediatric case in the United States.

J. Jennette, H. Hamrick, C. Laforce, 1984, The Journal of allergy and clinical immunology.

Fluticasone/Formoterol combination therapy compared with monotherapy in adolescent and adult patients with mild to moderate asthma.

C. Laforce, K. Kaiser, D. Pearlman, 2013, Clinical therapeutics.

Effect of ciclesonide and fluticasone on hypothalamic-pituitary-adrenal axis function in adults with mild-to-moderate persistent asthma.

M. Kaliner, B. Lipworth, H. Kaiser, 2005, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Inhibition of methylprednisolone elimination in the presence of erythromycin therapy.

R. Martin, S. Szefler, D. Leung, 1999, The Journal of allergy and clinical immunology.

Evaluation of Olopatadine Hydrochloride Nasal Spray, 0.6%, Used in Combination with an Intranasal Corticosteroid in Seasonal Allergic Rhinitis

E. Meltzer, B. Chipps, S. Tilles, 2010, Allergy and asthma proceedings.

QVA 149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease

R. Buhl, C. Laforce, M. Dolker, 2022 .

Long-term safety of tiotropium/olodaterol Respimat® in patients with moderate-to-very severe COPD and renal impairment in the TONADO® studies

U. Bothner, R. Buhl, E. Derom, 2018, Pneumologie.

Randomised, double-blind, placebo-controlled crossover study to investigate different dosing regimens of olodaterol delivered via Respimat® in patients with moderate to severe persistent asthma

M. Fležar, C. Laforce, K. Beeh, 2015, Respiratory Research.

The 24-h FEV1 time profile of olodaterol once daily via Respimat® and formoterol twice daily via Aerolizer® in patients with GOLD 2–4 COPD: results from two 6-week crossover studies

J. Bernstein, G. Feldman, C. Laforce, 2014, SpringerPlus.

Step-Up Therapy in Black Children and Adults with Poorly Controlled Asthma.

M. Cabana, J. Olin, E. Bleecker, 2019, The New England journal of medicine.

Mometasone furoate/formoterol reduces asthma deteriorations and improves lung function

P. Kuna, E. Meltzer, H. Nolte, 2011, European Respiratory Journal.

Mepolizumab improvements in health-related quality of life and disease symptoms in a patient population with very severe chronic rhinosinusitis with nasal polyps: psychometric and efficacy analyses from the SYNAPSE study

E. Kerwin, S. Yancey, W. Fokkens, 2023, Journal of Patient-Reported Outcomes.

Efficacy and safety of triamcinolone acetonide aqueous nasal spray in patients with seasonal allergic rhinitis.

C. Laforce, G. Feiss, Z. Munk, 1996, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Dose-Ranging and Cumulative Dose Studies of Albuterol Sulfate MDI in Co-Suspension Delivery™ Technology (AS MDI; PT007) in Patients with Asthma: the ASPEN and ANTORA Trials

E. Kerwin, C. Laforce, C. Reisner, 2021, Clinical Drug Investigation.

Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial.

E. Kerwin, E. Bleecker, D. Bernstein, 2017, The Lancet. Respiratory medicine.

Albuterol/budesonide for the treatment of exercise-induced bronchoconstriction in patients with asthma: the TYREE study.

F. Albers, A. Papi, B. Chipps, 2021, Annals of Allergy, Asthma & Immunology.

24-hour bronchodilator efficacy of single doses of indacaterol in patients with persistent asthma: comparison with placebo and formoterol

P. Korenblat, M. Higgins, C. Laforce, 2009, Current medical research and opinion.

Mometasone or Tiotropium in Mild Asthma with a Low Sputum Eosinophil Level.

Tonya S. King, M. Cabana, E. Israel, 2019, The New England journal of medicine.

Impact of exhaled nitric oxide measurements on treatment decisions in an asthma specialty clinic.

P. Dorinsky, C. Laforce, N. Herje, 2014, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Efficacy and safety of ciclesonide, 200 microg once daily, for the treatment of perennial allergic rhinitis.

E. Meltzer, S. Kunjibettu, C. Laforce, 2007, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Onset of action of mometasone furoate nasal spray (NASONEX) in seasonal allergic rhinitis.

C. Laforce, D. Bernstein, A. Rooklin, 1999, Allergy. European Journal of Allergy and Clinical Immunology.

Comparison of cetirizine-pseudoephedrine and placebo in patients with seasonal allergic rhinitis and concomitant mild-to-moderate asthma: randomized, double-blind study.

R. Nathan, P. Ratner, B. Kramer, 2006, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Validation of a New Portable Exhaled Nitric Oxide Analyzer, NIOX VERO®: Randomized Studies in Asthma

K. Alving, C. Laforce, G. Crater, 2017, Pulmonary Therapy.

Indacaterol provides sustained 24 h bronchodilation on once‐daily dosing in asthma: a 7‐day dose‐ranging study

L. Fabbri, M. Higgins, R. Owen, 2007, Allergy.

Patient Satisfaction with a Pressurized Metered-Dose Inhaler with an Integrated Dose Counter Containing a Fixed-Dose Mometasone Furoate/Formoterol Combination

E. Meltzer, R. Nathan, C. Weinstein, 2011, The Journal of asthma : official journal of the Association for the Care of Asthma.

Dose counter performance of mometasone furoate/formoterol inhalers in subjects with asthma or COPD.

N. Amar, C. Weinstein, C. Laforce, 2011, Respiratory medicine.

326 Nasal septal perforation in patients using intranasal beclomethasone depropionate (BDP)

C. Laforce, V. Davis, 1985 .

Safety and efficacy of once-daily treatment with beclomethasone dipropionate nasal aerosol in subjects with perennial allergic rhinitis.

E. Meltzer, R. Jacobs, S. Dunbar, 2012, Allergy and asthma proceedings.